Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Licensed GSK MenACWY vaccine · 1 trial · 1 indication
hSBA titers against N.meningitidis serogroup A were calculated in terms of GMTs adjusted for pre-vaccination titer.
| Arm | Type | Description |
|---|---|---|
| GSK3536820A ACWY_Liq Group | EXPERIMENTAL | Healthy adults, 18 to 40 years of age, receiving at Day 1 a single dose of investigational MenACWY liquid vaccine (GSK3536820A) formulation with approximately 30% Men A FS. |
| ACWY Group | ACTIVE_COMPARATOR | Healthy adults 18 to 40 years of age, receiving at Day 1 a single dose of licensed GSK's MenACWY vaccine formulation (Menveo). |
| Name | Type | Description |
|---|---|---|
| MenACWY liquid vaccine with approximately 30% MenA FS (GSK3536820A) | BIOLOGICAL | Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm |
| Licensed GSK MenACWY vaccine (Menveo) | BIOLOGICAL | Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm |
Inclusion Criteria: 1. Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol or subjects' parent(s)/Legally Acceptable Respresentative(s) \[LAR(s)\] who, in the opinion of the investigator, can and will comply, with the requirements of the proto...
The licensed GSK MenACWY vaccine is used for meningococcal infections, specifically to prevent disease caused by Neisseria meningitidis serogroups A, C, W, and Y. It is being studied in healthy adults aged 18 to 40 years to evaluate its safety and immunogenicity.
The licensed GSK MenACWY vaccine is developed by GSK plc, which trades under the ticker GSK. The company is conducting clinical research on this meningococcal vaccine to assess its safety and immune response in adult populations.
The licensed GSK MenACWY vaccine is in Phase 2 clinical development. It is an investigational vaccine, meaning it has not been approved for general use, and it is currently being evaluated in a completed Phase 2 trial involving healthy adults.
The licensed GSK MenACWY vaccine was studied in clinical trial NCT03652610, a Phase 2 study investigating the safety and immunogenicity of different formulations of GSK's meningococcal ACWY conjugate vaccine compared to Menveo. The trial enrolled 996 healthy adults aged 18 to 40 years across Australia, Belgium, Canada, Germany, and Italy.
The licensed GSK MenACWY vaccine is not the same as Menveo. In clinical trial NCT03652610, the GSK vaccine formulations (GSK3536820A and Menveo) were compared, with Menveo serving as an active control. The study assessed the safety and immunogenicity of the different formulations.
The licensed GSK MenACWY vaccine is a conjugate vaccine designed to elicit an immune response against meningococcal serogroups A, C, W, and Y. It works by presenting bacterial polysaccharides linked to a carrier protein to stimulate the immune system to produce protective antibodies.